ArticleERJ open research2022
Symptoms persisting after hospitalisation for COVID-19: 12 months interim results of the CO-FLOW study.
Article in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Long-term neurological and cognitive impact of COVID-19: a systematic review and meta-analysis in over 4 million patients.BMC neurology · 2025Pooled it
- Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025Pooled it
- Pooled it
- Global Prevalence of Long COVID, Its Subtypes, and Risk Factors: An Updated Systematic Review and Meta-analysis.Open forum infectious diseases · 2025Article
- Long-term multidimensional patient-centred outcomes after hospitalisation for COVID-19: do not only focus on disease severity.BMJ open respiratory research · 2025Article
- Health outcomes up to 3 years and post-exertional malaise in patients after hospitalization for COVID-19: a multicentre prospective cohort study (CO-FLOW).The Lancet regional health. Europe · 2025Article
- Article
- Long-term health outcomes of COVID-19 in ICU- and non-ICU-treated patients up to 2 years after hospitalization: a longitudinal cohort study (CO-FLOW).Journal of intensive care · 2024Article
- Supporting Evidence For Pulmonary Rehabilitation in the Treatment of Long COVID.Respiratory care · 2024Article
- The impact of pulmonary embolism on health outcomes of COVID-19 at 3 months after hospitalization.Research and practice in thrombosis and haemostasis · 2024Article
- Patients' evaluation of aftercare following hospitalization for COVID-19: satisfaction and unmet needs.Respiratory research · 2024Article
- Return to work and health-related quality of life up to 1 year in patients hospitalized for COVID-19: the CO-FLOW study.BMC medicine · 2023Article
- Nutritional status of patients with COVID-19 1-y post-ICU stay: A prospective observational study.Nutrition (Burbank, Los Angeles County, Calif.) · 2023Observational
- Year in Review: Long COVID and Pulmonary Rehabilitation.Respiratory care · 2023Review
- Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders.Dentistry journal · 2023Review
- Long-term outcome of COVID-19 patients treated with helmet noninvasive ventilation vs. high-flow nasal oxygen: a randomized trial.Journal of intensive care · 2023Article
- Two-year follow-up of patients with post-COVID-19 condition in Sweden: a prospective cohort study.The Lancet regional health. Europe · 2023Article
- COVID-19, A New Possible Mimicker of Interstitial Lung Disease Related to Primary Sjögren's Syndrome.Case reports in medicine · 2023Article
- Immunological profiling in long COVID: overall low grade inflammation and T-lymphocyte senescence and increased monocyte activation correlating with increasing fatigue severity.Frontiers in immunology · 2023Article
- The prolonged impact of COVID-19 on symptoms, health-related quality of life, fatigue and mental well-being: a cross-sectional study.Frontiers in epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A large proportion of patients experience a wide range of sequelae after acute COVID-19, especially after severe illness. The long-term health sequelae need to be assessed. Our objective was to longitudinally assess persistence of symptoms and clusters of symptoms up to 12 months after hospitalisation for COVID-19 and to assess determinants of the main persistent symptoms. Methods: In this multicenter prospective cohort study patients with COVID-19 are followed up for 2 years with measurements at 3, 6, 12 and 24 months after hospital discharge. Here, we present interim results regarding persistent symptoms up to 12 months. Results: We included 492 patients; mean±sd age was 60.2±10.7 years, 335 (68.1%) were males, median length of hospital stay was 11 (6.0-27.0) days. At 3 months after discharge 97.0% of the patients had at least one persisting symptom, this declined to 95.5% and 92.0% at 6 and 12 months, respectively (p=0.010). Muscle weakness, exertional dyspnoea, fatigue, and memory and concentration problems were the most prevalent symptoms with rates over 50% during follow-up. Over time, muscle weakness, hair loss and exertional dyspnoea decreased significantly (p<0.001), while other symptoms such as fatigue, concentration and memory problems, anosmia and ageusia persisted. Symptoms from the physical and respiratory cluster declined significantly over time, in contrast to the fatigue and cognitive symptom clusters. Conclusion: The majority of patients experienced COVID-19 sequelae up to 12 months after severe infection. Whereas physical and respiratory symptoms showed slow gradual decline, fatigue and cognitive symptoms did not evidently resolve over time.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.